Exacerbations · people with asthma
Tailored interventions based on sputum eosinophils probably leads to lower number of participants who had one or more exacerbations over the… compared with tailored interventions based on clinical symptoms (moderate certainty).
1 finding from 1 review
Hospital admissions · people with asthma
Tailored interventions based on sputum eosinophils probably leads to lower hospitalisations compared with tailored interventions based on clinical symptoms (moderate certainty).
1 finding from 1 review
Mean dose of inhaled corticosteroids per person per day (BUD equivalent mcg/day) · people with asthma
1 finding from 1 review
Mean daily use of oral corticosteroids per person per day · people with asthma
1 finding from 1 review
Cost of treatment per person at 1 year · people with asthma
1 finding from 1 review
Intervention not reported
Severe exacerbations requiring hospitalisation over the study period · Children from minority groups with doctor diagnosed asthma
The intervention showed no clear difference in severe exacerbations requiring hospitalisation over the study period (low certainty).
1 finding from 1 review
Intervention not reported
Number of exacerbations over 52 weeks · Children from minority groups with doctor diagnosed asthma
1 finding from 1 review
Intervention not reported
Number of participants who had one or more exacerbation of the study period · Adults from minority groups with doctor diagnosed asthma
It is very uncertain whether the intervention changes number of participants who had one or more exacerbation of the study… (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants requiring oral corticosteroids over the study period · Adults from minority groups with doctor diagnosed asthma
It is very uncertain whether the intervention changes number of participants requiring oral corticosteroids over the study… (very low certainty).
1 finding from 1 review
Intervention not reported
Severe exacerbations requiring hospitalisation over the study period · Adults from minority groups with doctor diagnosed asthma
It is very uncertain whether the intervention changes severe exacerbations requiring hospitalisation over the study period (very low certainty).
1 finding from 1 review
Number of participants who were not cured at · children < 24 months with ongoing symptoms (cough/wheeze) post‐acute bronchiolitis
Antibiotics showed no clear difference in number of participants who were not cured at compared with placebo or no treatment (low certainty).
1 finding from 1 review
Number of participants rehospitalised for a respiratory illness · children < 24 months with ongoing symptoms (cough/wheeze) post‐acute bronchiolitis
Antibiotics showed no clear difference in number of participants rehospitalised for a respiratory illness compared with placebo or no treatment (low certainty).
1 finding from 1 review
Proportion of participants with recurrent wheeze · children < 24 months with ongoing symptoms (cough/wheeze) post‐acute bronchiolitis
Antibiotics showed no clear difference in proportion of participants with recurrent wheeze compared with placebo or no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Patients with ≥ 1 exacerbations requiring oral corticosteroids Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
The intervention probably leads to lower patients with ≥ 1 exacerbations requiring oral corticosteroids… (moderate certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in mean asthma symptom score Greater the reduction, better the outcome Duration of trials: 12 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Overall adverse effects Duration of trials: 8 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 16 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Death Duration of trials: 12 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
% change from baseline ICS dose Duration of trials: 12 to 24 weeks More reduction is better · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Participants with ≥ 1 exacerbation requiring oral corticosteroids Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in participants with ≥ 1 exacerbation requiring oral corticosteroids… (low certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in morning PEFR (L/min) Duration of trials: 12 to 24 weeks · adults and adolescents with persistent asthma
1 finding from 1 review